Switching algorithms: from one immunomodulatory agent to another

Rating neurologic impairment in multiple sclerosis

1983 • 14,011 citations

Randomized controlled trial of interferon-beta-1a in secondary progressive MS

2001 • 461 citations

Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double‐blind, placebo‐controlled trial

2007 • 416 citations

Defining the response to interferon‐β in relapsing‐remitting multiple sclerosis patients

2006 • 315 citations

Guidelines on use of anti‐IFN‐β antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN‐β antibodies in multiple sclerosis

2005 • 228 citations

Clinical course after change of immunomodulating therapy in relapsing–remitting multiple sclerosis

2006 • 67 citations

Homer 3 autoimmunity in subacute idiopathic cerebellar ataxia

2007 • 59 citations

Identifying and treating patients with suboptimal responses

2004 • 56 citations

Demographic and health-related factors associated with complementary and alternative medicine (CAM) use in multiple sclerosis

2005 • 51 citations

A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting

2006 • 50 citations

Glatiramer acetate in treatment-naive and prior interferon-beta-1b-treated multiple sclerosis patients*

2006 • 49 citations

Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing–remitting MS

2007 • 46 citations

Neutralising antibodies to interferon β in multiple sclerosis

2007 • 43 citations

Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience

2005 • 34 citations

The efficacy of glatiramer acetate in beta-interferon-intolerant MS patients

2005 • 26 citations